Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-20T13:43:40.860Z Has data issue: false hasContentIssue false

Comorbidity of anxiety and depression

Published online by Cambridge University Press:  16 April 2020

P. Van Oppen
Affiliation:
Department of Psychiatry, GGZBA/VUMC, Amsterdam, The Netherlands
J.H. Smit
Affiliation:
Department of Psychiatry, GGZBA/VUMC, Amsterdam, The Netherlands
A.J.L.M. Van Balkom
Affiliation:
Department of Psychiatry, GGZBA/VUMC, Amsterdam, The Netherlands
F. Zitman
Affiliation:
Department of Psychiatry, LUMC, Leiden, The Netherlands
W.A. Nolen
Affiliation:
Department of Psychiatry, UMCG, Groningen, The Netherlands
A.T. Beekman
Affiliation:
Department of Psychiatry, GGZBA/VUMC, Amsterdam, The Netherlands
R. Van Dyck
Affiliation:
Department of Psychiatry, GGZBA/VUMC, Amsterdam, The Netherlands
B.W. Penninx
Affiliation:
Department of Psychiatry, GGZBA/VUMC, Amsterdam, The Netherlands

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Epidemiological studies have shown that anxiety disorders and depressive disorders frequently co-occur. Comorbidity studies revealed that estimations on comorbidity patterns of anxiety disorder and depressive disorders differs widely (30-80%). These differences may be due to different sampling-frames (community sample; primary care sample; secondary care sample). Our data were derived from the first wave of the Netherlands Study on Depression and Anxiety (NESDA), a 10-year longitudinal study on the long term prognosis of anxiety and depression. In our sample, 1285 subjects (52%) had a Major Depressive Disorder and/or an anxiety disorder (GAD; Social Phobia, PD with or without agoraphobia; agoraphobia alone) measured with the CIDI. These subjects were recruited from the general population (9%), in primary care (46%) and in specialized mental health care (44%). Of the 870 subjects with a MDD in the previous 6-months, 60% had an anxiety disorder (6-months) and 71% had an life-time anxiety disorder. Of the 937 subjects with a PD, GAD, Social Phobia or Agoraphobia in the previous 6-months, 56% had a MDD (6-months) and 70% had an life-time MDD. As expected comorbidity between anxiety disorders and MDD were significantly higher for subjects recruited in specialized mental health care settings (50%), then for subjects recruited in primary health-care facilities (34%) and for subject recruited from general population (27%)(p<.001). These preliminary findings suggested high levels of comorbidity between MDD and anxiety disorder. Furthermore, our findings demonstrated higher comorbidity patterns for subjects in specialized mental health care-settings.

Type
Poster Session 2: Epidemiology
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.